Abstract
ABSTRACTIntroduction: Unselective approaches of immunotherapy in metastatic renal cell cancer (mRCC) have been largely abandoned over the past decade. Despite the established clinical benefit of tyrosine kinase inhibitors for mRCC and the recent successful implementation of immune check-point inhibition, specific immunotherapy may additionally contribute to anti-cancer immune response with good tolerability and long-term clinical benefit.Areas covered: AGS-003 represents an approach of specific immunotherapy using a dendritic cell-based vaccine based on monocyte derived dendritic cells, which are co-electroporated with individual antigen coding amplified tumor RNA and synthetic CD40L RNA. After successful clinical phase I and II trials, current evaluation of AGS-003 in mRCC in combination with sunintib is under way in a phase III clinical trial and results are awaited.Expert commentary: Initial results from clinical evaluation of AGS-003 are promising also based on the underlying mechanistic rationale. Toxicity profiles in combinatory regimens are mainly attributed to the side effects of the respective drugs. Apart from further awaited results of the oncologic efficacy of AGS-003 in mRCC, it will be of interest how the preparation of the compound ex vivo and issues related to cost and logistics will affect a potential clinical application of AGS-003 in the daily routine practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Expert Review of Precision Medicine and Drug Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
